oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes SELECT Trial Clinical Effectiveness and Safety of
Description
Before starting GLP-1 medications: Ensure you've had a recent diabetic eye screening (within the past 12 months) Discuss your retinopathy status with your prescribing clinician If you have known retinopathy, consider ophthalmology review before initiation Understand that gradual dose titration may help avoid very rapid changes in blood glucose, which is a general principle in diabetes management During treatment: Attend all scheduled diabetic eye screening appointments without fail If you have pre-existing retinopathy, your diabetes team may consider more frequent monitoring based on your individual clinical situation Control blood pressure to target levels (below 140/90 mmHg, or below 130/80 mmHg if you have kidney, eye or cerebrovascular damage, if tolerated) Maintain good overall glycaemic control whilst avoiding excessively rapid HbA1c reductions when possible Stop smoking if applicable, as tobacco significantly worsens diabetic eye disease Manage cholesterol levels according to NICE guidance for cardiovascular risk reduction Communicate openly with your healthcare team about any visual symptoms, even if they seem minor
10.7150/thno.15993 334
Current evidence suggests Retatrutide may produce slightly more weight loss than Tirzepatide due to its triple-action mechanism
10.1128/mBio.01438-14 389
Reduced carbohydrate cravings One of the underappreciated benefits of this combination is how semaglutide makes keto adherence dramatically easier
Contact your GP if you experience these symptoms, as neurological damage from B12 deficiency can become irreversible if left untreated
